{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:19:17Z","timestamp":1793999957924,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"F Hoffmann-La Roche - funded study and medical writing support"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Faricimab Real-World Evidence (FARWIDE) studies are evaluating real-world outcomes of eyes with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) treated with faricimab in the UK. Here, we present results from FARWIDE\u2013nAMD for eyes with 12 months of follow-up after faricimab initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>nAMD patient-eyes that received \u22651 faricimab injection after May 2022 at one of 35 participating UK National Health Service retinal clinics with \u226512 months of follow-up after faricimab initiation as of July 2024 were included. Treatment-na\u00efve (TN) eyes had no prior anti-VEGF treatment. Previously treated (PT) eyes switched from an anti-VEGF to faricimab. Baseline characteristics, VA, and injection frequency were assessed. Intraocular inflammation (IOI) and presumed infectious endophthalmitis (PIE) rates were pooled for nAMD and DMO eyes with any follow-up duration on faricimab. Analyses are descriptive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>5854 nAMD patients (6991 eyes; 26.5% TN, 73.5% PT) were included. 83.3% of PT eyes switched from aflibercept 2.0\u2009mg. TN eyes received a mean (SD) of 4.7 (0.7) faricimab injections in months 1\u20136 and 2.2 (1.1) injections in months 7\u201312. PT eyes received 4.5 (1.0) injections in months 1\u20136 and 3.0 (1.2) in months 7\u201312. In TN eyes, mean (SD) VA increased from 56.4 (16.3) Early Treatment Diabetic Retinopathy Study letters at baseline to 60.1 (19.4) at 12 months (mean [SD] change 3.6 [14.7] letters). PT eyes had stable VA. IOI and PIE rates were consistent with faricimab phase 3 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These 1-year data support real-world faricimab effectiveness, durability, and safety in nAMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04213-2","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:44:30Z","timestamp":1773135870000},"page":"1128-1137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study"],"prefix":"10.1038","volume":"40","author":[{"given":"James","family":"Talks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1185-6942","authenticated-orcid":false,"given":"Gabriella","family":"de Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-4067","authenticated-orcid":false,"given":"Praveen J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R.","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0213-6253","authenticated-orcid":false,"given":"Richard P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-243X","authenticated-orcid":false,"given":"Martin","family":"McKibbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-0381","authenticated-orcid":false,"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhianon","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-4512","authenticated-orcid":false,"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4424-9129","authenticated-orcid":false,"given":"Christine A.","family":"Kiire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalee","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8748-5299","authenticated-orcid":false,"given":"Melanie","family":"Dodds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Dayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"4213_CR1","volume":"14","author":"H Vyawahare","year":"2022","unstructured":"Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14:e29583.","journal-title":"Cureus"},{"key":"4213_CR2","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Age-related macular degeneration preferred practice pattern(R). Ophthalmology. 2020;127:P1\u2013P65.","journal-title":"Ophthalmology"},{"key":"4213_CR3","unstructured":"European Medicines Agency. Eyelea. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eylea."},{"key":"4213_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A, et al. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258:2077\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4213_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2018;2:645\u201353.","journal-title":"Ophthalmol Retina"},{"key":"4213_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, Gentile B, Chi GC, Mirt M, et al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence. 2022;16:587\u2013604.","journal-title":"Patient Prefer Adherence"},{"key":"4213_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4213_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0401-y","volume":"17","author":"F Ziemssen","year":"2017","unstructured":"Ziemssen F, Feltgen N, Holz FG, Guthoff R, Ringwald A, Bertelmann T, et al. Demographics of patients receiving intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmol. 2017;17:7.","journal-title":"BMC Ophthalmol"},{"key":"4213_CR9","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.2147\/OPTH.S275977","volume":"14","author":"H Mehta","year":"2020","unstructured":"Mehta H, Kim LN, Mathis T, Zalmay P, Ghanchi F, Amoaku WM, et al. Trends in real-world neovascular AMD treatment outcomes in the UK. Clin Ophthalmol. 2020;14:3331\u201342.","journal-title":"Clin Ophthalmol"},{"key":"4213_CR10","unstructured":"National Institute for Health and Care Excellence. Faricimab for treating diabetic macular oedema\u2013technology appraisal guidance. 2022. https:\/\/www.nice.org.uk\/guidance\/ta799\/resources\/faricimab-for-treating-diabetic-macular-oedema-pdf-82611625700293."},{"key":"4213_CR11","unstructured":"Food and Drug Administration. Vabysmo Prescribing Information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761235s000lbl.pdf."},{"key":"4213_CR12","unstructured":"European Medicines Agency. Vabysmo. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vabysmo."},{"key":"4213_CR13","doi-asserted-by":"publisher","first-page":"1192464","DOI":"10.3389\/fncel.2023.1192464","volume":"17","author":"J Canonica","year":"2023","unstructured":"Canonica J, Foxton R, Garrido MG, Lin CM, Uhles S, Shanmugam S, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion. Front Cell Neurosci. 2023;17:1192464.","journal-title":"Front Cell Neurosci"},{"key":"4213_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"4213_CR15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: 2-year results from the phase 3 nAMD trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914\u201326.","journal-title":"Ophthalmology"},{"key":"4213_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13:8747.","journal-title":"Sci Rep"},{"key":"4213_CR17","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","volume":"261","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H. Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261:2945\u201352.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4213_CR18","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/OPTH.S463624","volume":"18","author":"NQX Quah","year":"2024","unstructured":"Quah NQX, Javed K, Arbi L, Hanumunthadu D. Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2024;18:1479\u201390.","journal-title":"Clin Ophthalmol"},{"key":"4213_CR19","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye. 2023;37:3282\u20139.","journal-title":"Eye"},{"key":"4213_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Felfel T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2024;8:537\u201344.","journal-title":"Ophthalmol Retina"},{"key":"4213_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real-world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye. 2024;38:3059\u201364.","journal-title":"Eye"},{"key":"4213_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"key":"4213_CR23","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201\u20138.","journal-title":"Clin Ophthalmol"},{"key":"4213_CR24","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.2147\/OPTH.S395279","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041\u20136.","journal-title":"Clin Ophthalmol"},{"key":"4213_CR25","unstructured":"Scottish Government. Scottish Index of Multiple Deprivation (SIMD) 2020. 2020. https:\/\/www.spatialdata.gov.scot\/geonetwork\/srv\/eng\/catalog.search."},{"key":"4213_CR26","unstructured":"UK Government. English Indices of Deprivation 2019. The English Indices of Deprivation 2019 (IoD 2019). 2019. https:\/\/assets.publishing.service.gov.uk\/media\/5d8b399a40f0b609946034a4\/IoD2019_Infographic.pdf."},{"key":"4213_CR27","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30:1046\u201350.","journal-title":"Retina"},{"key":"4213_CR28","unstructured":"Norridge CFEG-GM, McKibbin M, Donachie PHJ. National Ophthalmology Database Audit 2023. 2023. https:\/\/nodaudit.org.uk\/sites\/default\/files\/2023-02\/NOD%20AMD%20Audit%20Full%20Annual%20Report%202023_0.pdf"},{"key":"4213_CR29","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye. 2024;38:3569\u201377.","journal-title":"Eye"},{"key":"4213_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitr. 2024;10:5.","journal-title":"Int J Retina Vitr"},{"key":"4213_CR31","unstructured":"Lim JI, Tabano D, Ali F, et al. 12-month real-world clinical and anatomical outcomes with faricimab in patients with neovascular age-related macular degeneration: FARETINA-AMD. 24th EURETINA Congress; Barcelona, Spain; 19\u201322 September 2024."},{"key":"4213_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","volume":"9","author":"SY Sim","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Patel PJ, et al. Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. 2025;9:22\u201330.","journal-title":"Ophthalmol Retina"},{"key":"4213_CR33","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/03007995.2024.2362278","volume":"40","author":"S Sivaprasad","year":"2024","unstructured":"Sivaprasad S, Bailey C, Downey L, Gilbert R, Gale R, Kotagiri A, et al. Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Curr Med Res Opin. 2024;40:1221\u201333.","journal-title":"Curr Med Res Opin"},{"key":"4213_CR34","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s40123-024-00999-8","volume":"13","author":"T Li","year":"2024","unstructured":"Li T, Berdunov V, Hamilton R, Rojas YG, B\u00fchrer C, Cox O, et al. Economic assessment in resource-constrained systems: individual-level simulation model in wet age-related macular degeneration and diabetic macular oedema. Ophthalmol Ther. 2024;13:2577\u201397.","journal-title":"Ophthalmol Ther"},{"key":"4213_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/aos.16774","volume":"103","author":"S Abdalla","year":"2025","unstructured":"Abdalla S, Westborg I, Pulkki-Br\u00e4nnstr\u00f6m A-M, Norberg H. Faricimab versus bevacizumab for neovascular age-related macular degeneration: cost analysis based on real-world data from the Swedish Macula Registry. Acta Ophthalmol. 2025;103:99\u2013108.","journal-title":"Acta Ophthalmol"},{"key":"4213_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.oret.2023.12.001","volume":"8","author":"B Momenaei","year":"2024","unstructured":"Momenaei B, Wang K, Kazan AS, Oh GJ, Ni RL, Wakabayashi T, et al. Rates of ocular adverse events after intravitreal faricimab injections. Ophthalmol Retina. 2024;8:311\u20133.","journal-title":"Ophthalmol Retina"},{"key":"4213_CR37","first-page":"245","volume":"65","author":"A Montesel","year":"2024","unstructured":"Montesel A, Sacconi R, Nicholson L, Chhablani J, Yzer S, Mohabati D, et al. Intraocular inflammation associated with faricimab therapy: the Moorfields experience. Investig Ophthalmol Vis Sci. 2024;65:245.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4213_CR38","unstructured":"Roche Registration GmbH. Faricimab Summary of Product Characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf."},{"key":"4213_CR39","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study-6-month results. Eye. 2023;37:3574\u201381.","journal-title":"Eye"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04213-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:59:38Z","timestamp":1779368378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04213-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4213"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04213-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JT: Advisory Board: Bayer, Roche; Consultancy: Bayer, Roche; Speaker: Alimera, Bayer, Heidelberg Engineering, Roche; Travel Support: Bayer, Heidelberg Engineering, Roche; Research: Bayer, Boehringer Ingelheim, Janssen, Roche. GdS: Advisory Board: AbbVie, Apellis, Astellas, Bayer, Novartis, Roche, Teva; Consultancy: Boehringer Ingelheim, Roche; Speaker\/Travel Support: AbbVie, Bayer, Heidelberg Engineering, Novartis, Roche. Section Editor: Eye Journal. PJP: Advisory Board: Bayer, Boehringer Ingelheim, Genentech, Inc., Novartis, Roche; Honoraria\/Educational Grant: Bayer, Roche; Research Funding: Bayer. SRdS: Consultancy: AbbVie, Bayer, Roche; Travel Support: Bayer, Roche. RPG: AbbVie, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Novartis, Ocular Therapeutix, Roche, Santan. MM: Advisory Board: Apellis, Roche; Consultancy: Roche; Speaker: Bayer; Travel Support\/Educational Grant: Bayer, Roche. DV: Advisory Board\/ Honoraria: AbbVie, Astellas, Bayer, Outlook Therapeutics, Roche, Teva; Educational Travel Grants: AbbVie, Alimera, Bayer, Roche; Clinical Trial PI: AbbVie, Bayer, EyeBio, Novartis, Roche. IP: Advisory Board\/Consulting\/Honoraria\/Travel Expenses: Roche. TP: Advisory Board: Alimera, Allergan, Apellis, Bayer, Novartis, Optos, Roche, ZEISS; Consultancy: Boehringer Ingelheim, Roche; Investigator-Initiated Grant: Boehringer Ingelheim, Novartis; Speaker: Alimera, Allergan, Bayer, Heidelberg Engineering, Novartis, Optos, ZEISS. RR: Advisory Board\/Honoraria: Roche; Grant Support: Macular Society. CB: Advisory Board\/Honoraria\/Travel Support: Alimera, Apellis, Bayer, Boehringer Ingelheim, Janssen, Novartis, Roche. LD: Advisory Board\/Honoraria: Alimera, Allergan, Bayer, Biogen, Novartis, Roche; Travel Grants: Allergan, Bayer, Novartis. CK: Advisory Board\/Consulting\/Honoraria\/Travel Expenses: Alimera, Bayer, Boehringer Ingelheim, Roche. SS: Funding\/Fees: AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, EyeBio, EyePoint, Janssen, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Kriya Therapeutics, Roche, Sanofi, Stealth. AKD: Employee: F. Hoffmann-La Roche Ltd., NJ: Employee: Roche Products Ltd., GC: Employee: Genentech, Inc., MD: Employee: Medisoft Ltd., PD: Employee: Genentech, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}